For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Eyepoint Pharmaceuticals, Inc.

USPTO Granted Patents = 19

CIPO Patents = 2

EPO Patents = 4

Forward Citations = 32

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Kevin Gene Peters (11 out of 34 patents)

John M Janusz (3 out of 36 patents)

Hong Guo (2 out of 2 patents)

4. Jianbing Chen (2 out of 2 patents)

5. Michael Allen Flynn (2 out of 6 patents)

6. Robert A Shalwitz (2 out of 33 patents)

7. Evan Williams (2 out of 6 patents)

8. Michael W Metz (2 out of 2 patents)

9. Alexander Smith (1 out of 16 patents)

10. Martin Nazzaro (1 out of 7 patents)

11. Josh York (1 out of 5 patents)

12. Ron Leblanc (1 out of 5 patents)

13. Rocco Jamie Rotello (1 out of 4 patents)

14. Michael Glenn Davis (1 out of 8 patents)

15. Michelle Howard-sparks (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. D1106444 - Ocular injector (2025-12-16),

2. 12329859 - Bioerodible drug delivery devices (2025-06-17),

3. 12187715 - Small molecule activators of Tie-2 (2025-01-07),

4. 12171751 - Methods of treating intraocular pressure with activators of Tie-2 (2024-12-24),

5. 12152023 - Compositions, formulations and methods for treating ocular diseases (2024-11-26),

6. 12145986 - Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta) (2024-11-19),

7. D1043969 - Ocular injector (2024-09-24),

8. 12064420 - Tie-2 activators targeting the Schlemm's canal (2024-08-20),

9. D1037439 - Ocular injector (2024-07-30),

10. 12043664 - Methods for treating vascular leak syndrome and cancer (2024-07-23),

11. 11873334 - Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF (2024-01-16),

12. 11814425 - Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof (2023-11-14),

13. 11666558 - Methods of treating intraocular pressure with activators of Tie-2 (2023-06-06),

14. 11613534 - Small molecule activators of Tie-2 (2023-03-28),

15. 11413242 - Formulations of Tie-2 activators and methods of use thereof (2022-08-16),

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. The company's proprietary technology platform, Durasert, delivers sustained release drug therapies to target specific ocular conditions. With a focus on improving patient outcomes and quality of life, EyePoint Pharmaceuticals is dedicated to advancing eye care through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#20 in Watertown, MA

#1,008 in Massachusetts

#16,629 in US

#31,713 in the World

Watertown, MA, United States of America

Eyepoint Pharmaceuticals, Inc.

Forward Citations = 32

18 inventors:

Kevin Gene Peters (11 out of 34 patents)

John M Janusz (3 out of 36 patents)

Hong Guo (2 out of 2 patents)

4. Jianbing Chen (2 out of 2 patents)

5. Michael Allen Flynn (2 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…